Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) - Join Clinical Trial NCTNCT05512364
How to Join This Clinical Trial - NCTNCT05512364
Learn how to participate in this PHASE3 trial studying an investigational therapy for ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer. This study is currently enrolling participants.
Am I Eligible for This Clinical Trial?
This clinical research study is looking for participants with ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.
- Condition Being Studied
- ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
- Treatment Being Tested
- Investigational treatment
- Study Phase
- PHASE3 - Large-scale efficacy study
- Enrollment Status
- Currently enrolling participants
- Study Identifier
- NCTNCT05512364 - ClinicalTrials.gov Identifier
- Sponsored By
- Study sponsor
What to Expect as a Participant
Participating in this clinical trial involves:
- Initial screening to determine eligibility
- Regular study visits and health assessments
- Receiving the study treatment or placebo
- Medical monitoring and follow-up care
- Contributing to medical research that may help others
- Potential access to new treatments before they're widely available
Clinical Trial Benefits and Compensation
Participants in this clinical research study may receive:
- Close medical monitoring by healthcare professionals
- Access to potential new treatments
- Compensation for time and travel (varies by study)
- No-cost study-related medical care
- The opportunity to help advance medical knowledge
Where Is This Clinical Trial Located?
This study is enrolling participants at 94 locations. Find a study site near you:
Clinical Research Site
Anderlecht, 1070 - Belgium
Status: RECRUITING
Clinical Research Site
Brasschaat, 2930 - Belgium
Status: RECRUITING
Clinical Research Site
Brussels, 1200 - Belgium
Status: RECRUITING
Clinical Research Site
Charleroi, 6000 - Belgium
Status: RECRUITING
Clinical Research Site
Haine-Saint-Paul, 7100 - Belgium
Status: RECRUITING
Clinical Research Site
Kortrijk, 8500 - Belgium
Status: RECRUITING
Clinical Research Site
Leuven, 3000 - Belgium
Status: RECRUITING
Clinical Research Site
Namur, 5000 - Belgium
Status: RECRUITING
Clinical Research Site
Roeselare, 8800 - Belgium
Status: RECRUITING
Clinical Research Site
Turnhout, 2300 - Belgium
Status: RECRUITING
And 84 more locations available. Contact us to find the nearest participating site.
How to Enroll in This Study
To learn more about participating in this PHASE3 clinical trial for ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer:
- Review the eligibility criteria with your healthcare provider
- Contact the study team for a pre-screening interview
- Schedule an in-person screening visit if eligible
- Review and sign the informed consent form
- Begin participation in the clinical trial
Why Choose Quri.ai Study Finder
Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:
- Discover clinical trials before competitors
- Access exclusive contact information
- Track sponsor pipelines and opportunities
- Connect with decision makers directly
- Win more business partnerships